While we partner with companies at all stages, we prefer to be involved from the very beginning, to help setting the strategy, recruiting key R&D scientists and providing connections to corporates.
We are fortunate to have been the first investor in major biotechs in Korea, such as PH Pharma, ViroMed, Qurient.
We aim to help aspiring entrepreneurs to build great companies, from bench to IPO and beyond.
Cross-border healthcare platform company with diversified clinical stage NCE/NBE pipelines
Biotechnology company with focus on the development of DNA, Protein and cell-based biotherapeutics
Biotechnology company with unique virtual R&D model, developing novel therapeutics against infectious disease and inflammation
Pharmaceutical company focusing on the development of IMDs
Protein based drug discovery and development company
Clinical-stage biotech company, developing human therapeutic antibodies for the treatment of cancer and inflammatory diseases
Biotech with focus on developing stem cell therapies for CNS disorders
Medical devices company with focus on the manufacture of skin care and personal beauty equipment
The largest Pre-clinical CRO in Korea
Pre-clinical CRO specializing in project management of IND-enabling studies
Broadhill Ventures led the Series C round funding, with backing from major VC firms in Korea. With its latest round of funding, PH Pharma has raised approximately $60M to date and is set to list on KOSDAQ in 2H, 2020. Advising the company listing strategy.
Broadhill Ventures led Series A round of $6M. We partnered from inception of the company and helped to create the current team.
11F, Teheran-ro 528, Gangnam-gu, Seoul, Republic of Korea